TrialFrontiers in immunology2023

Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial.

Pascal Urwyler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.